Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1991-8-7
|
pubmed:abstractText |
The purpose of the study was to evaluate the short- and long-term immunity after intranasal vaccination in pigs with maternally derived antibodies (MDA). In two experiments, 10-week-old pigs with moderate MDA titres against Aujeszky's disease virus (ADV) were vaccinated intranasally with the Bartha strain of ADV to evaluate the protective immunity conferred at 2 weeks, 2 months and 4 months after vaccination. Protection was evaluated on the basis of severity of clinical signs, periods of fever and growth arrest, and duration and amount of virus excreted after challenge with a virulent ADV. During the first 2-3 weeks after vaccination, antibodies to ADV continued to decline as in unvaccinated control pigs. After that, antibody titres stabilized or gradually increased. At 2 weeks, 2 months and 4 months after vaccination, vaccinated pigs were significantly better protected than unvaccinated controls. The vaccinated pigs challenged 2 weeks after vaccination hardly developed any sign of disease. Mild signs of Aujeszky's disease and a growth arrest period of 5 days were observed in vaccinated pigs challenged 2 months after vaccination, whereas vaccinated pigs challenged 4 months after vaccination developed severe signs of disease and a growth arrest period of 13 days. Vaccinated pigs challenged 2 weeks after vaccination did not excrete challenge virus, and pigs challenged 2 or 4 months after vaccination excreted far less virus than unvaccinated controls. The results demonstrate that intranasal ADV vaccination of pigs with moderate MDA titres protected them from 2 weeks to at least 4 months after vaccination. Immunity steadily declined, however, after vaccination.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0378-1135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
103-13
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1648282-Administration, Intranasal,
pubmed-meshheading:1648282-Animals,
pubmed-meshheading:1648282-Antibodies, Viral,
pubmed-meshheading:1648282-Body Temperature,
pubmed-meshheading:1648282-Body Weight,
pubmed-meshheading:1648282-Herpesvirus 1, Suid,
pubmed-meshheading:1648282-Immunity, Maternally-Acquired,
pubmed-meshheading:1648282-Neutralization Tests,
pubmed-meshheading:1648282-Pseudorabies,
pubmed-meshheading:1648282-Random Allocation,
pubmed-meshheading:1648282-Specific Pathogen-Free Organisms,
pubmed-meshheading:1648282-Swine,
pubmed-meshheading:1648282-Swine Diseases,
pubmed-meshheading:1648282-Vaccines, Attenuated,
pubmed-meshheading:1648282-Viral Vaccines
|
pubmed:year |
1991
|
pubmed:articleTitle |
Intranasal vaccination of pigs against Aujeszky's disease: protective immunity at 2 weeks, 2 months and 4 months after vaccination in pigs with maternal antibodies.
|
pubmed:affiliation |
Central Veterinary Institute, Department of Virology, Lelystad, Netherlands.
|
pubmed:publicationType |
Journal Article
|